Role of Magnesium Supplementation in the Treatment of Depression
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Depression, Depression |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/14/2017 |
| Start Date: | May 2015 |
| End Date: | May 2018 |
The objective of this project is to test the hypothesis that magnesium supplementation will
decrease depressive symptoms in adults.
This study takes place over 12 consecutive weeks. While the investigators will follow the
volunteers for the full 12 weeks volunteers will only take magnesium supplements for 6
consecutive weeks. Volunteers will be randomly assigned to start the supplement at week 1 or
week 7. Volunteers will take two supplement two times a day for a total of 248 mg elemental
magnesium daily in the form of magnesium chloride. This amount of magnesium is less than the
tolerable upper limit of 350 mg per day. The supplements will be provided. Volunteers will be
asked to maintain their normal diet for the 12 weeks of the study.
The primary outcome measure is the PHQ-9 questionnaire, a validated measure of depression.
Secondary measures include the GAD-7 for Anxiety and side effects.
decrease depressive symptoms in adults.
This study takes place over 12 consecutive weeks. While the investigators will follow the
volunteers for the full 12 weeks volunteers will only take magnesium supplements for 6
consecutive weeks. Volunteers will be randomly assigned to start the supplement at week 1 or
week 7. Volunteers will take two supplement two times a day for a total of 248 mg elemental
magnesium daily in the form of magnesium chloride. This amount of magnesium is less than the
tolerable upper limit of 350 mg per day. The supplements will be provided. Volunteers will be
asked to maintain their normal diet for the 12 weeks of the study.
The primary outcome measure is the PHQ-9 questionnaire, a validated measure of depression.
Secondary measures include the GAD-7 for Anxiety and side effects.
Inclusion Criteria:
- All adults at least 18 years of age
- A Patient Health Questionnaire-9 (PHQ-9) score of greater or equal to 5 but less than
20
- People who are currently being treated for depression are still eligible to
participate but their treatment must be stable (no changes in medication dose or brand
and/or no changes in therapy regimen for at least 2 months).
Exclusion Criteria:
- Active delirium or dementia
- Medicinal treatment for bipolar disorder, personality disorder or schizophrenia,
- Glomerular Filtration Rate of less than 60
- Irritable Bowel Disease
- Inflammatory Bowel Disease
- GERD
- Gastritis
- Pregnant as reported by potential volunteer
- Myasthenia Gravis
- Planned elective surgery
- Currently taking
- Long Term Antibiotics
- Fluoroquinolone
- Trientine or Penicillamine
- Long Term Antivirals
- Digoxin
- Bisphosphonates
- Eltrombopag
- Opiods
- Calcium Channel Blockers
- Deferiprone
- Doxercalciferol
- Unable or unwilling to stop taking a MVI or magnesium supplement
We found this trial at
1
site
University of Vermont The University of Vermont combines faculty-student relationships most commonly found in a...
Click here to add this to my saved trials
